[HTML] nature.com

[HTML][HTML] Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

V Dussupt, RS Sankhala, L Mendez-Rivera… - Nature …, 2021 - nature.com
Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …
被引用次数：39 相关文章
[HTML] nih.gov

[HTML][HTML] Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

V Dussupt, RS Sankhala, L Mendez-Rivera… - Nature …, 2021 - ncbi.nlm.nih.gov
Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

V Dussupt, RS Sankhala, L Mendez-Rivera… - Nature …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Prevention of viral escape and increased
coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants …

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.

V Dussupt, RS Sankhala, L Mendez-Rivera… - Nature …, 2021 - europepmc.org
Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

V Dussupt, RS Sankhala, L Mendez-Rivera… - Nature …, 2021 - osti.gov
AbstractPrevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

V Dussupt, RS Sankhala… - Nature …, 2021 - pubmed.ncbi.nlm.nih.gov
Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

V Dussupt, RS Sankhala, L Mendez-Rivera… - Nature …, 2021 - osti.gov
AbstractPrevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …